l e t t e r s Drug-induced liver injury (DILI) limits the development and application of many therapeutic compounds and presents major challenges to the pharmaceutical industry and clinical medicine 1,2 . Acetaminophen-containing compounds are among the most frequently prescribed drugs and are also the most common cause of DILI 3 . Here we describe a pharmacological strategy that targets gap junction communication to prevent amplification of fulminant hepatic failure and acetaminopheninduced hepatotoxicity. We demonstrate that connexin 32 (Cx32), a key hepatic gap junction protein, is an essential mediator of DILI by showing that mice deficient in Cx32 are protected against liver damage, acute inflammation and death caused by liver-toxic drugs. We identify a small-molecule inhibitor of Cx32 that protects against liver failure and death in wild-type mice when co-administered with known hepatotoxic drugs. These findings indicate that gap junction inhibition could provide a pharmaceutical strategy to limit DILI and improve drug safety.
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Drug safety is an important public health concern affecting the pharmaceutical industry, regulatory agencies, physicians and patients. The decision to develop, approve and prescribe a drug requires that the therapeutic benefits of medications be continuously weighed against their potential toxicities 1, 4 . The liver represents an important target of drug toxicity because it metabolizes exogenous compounds into reactive intermediates, which can then cause progressive hepatocyte damage, fulminant hepatic failure and death if liver transplantation is not performed 5 . Due to its association with substantial patient morbidity and mortality, DILI is the most frequently cited reason for abandoning compounds early in development or withdrawing them from the market after approval 1, 6 . Moreover, many drugs, most notably acetaminophen, are limited in dosage because of their potential to induce liver injury 7 .
The pathogenesis of DILI involves a multiphase process that exhibits marked spatial heterogeneity 2, [8] [9] [10] . The liver is functionally heterogeneous at baseline, with the majority of P450 enzyme expression and drug metabolism occurring in hepatocytes near the central veins 11 . In the initial phase of acute DILI, the perivenular cells are preferentially injured by reactive drug metabolites whereas the rest of the parenchyma remains viable 11 . The initial direct injury, which can be dose-dependent or idiosyncratic, subsequently progresses to involve the entire hepatic lobule through host immune mechanisms that remain poorly defined 12 .
Acetaminophen, the most common cause of DILI, results in hepatocellular damage that continues to occur even after the concentration of circulating hepatotoxin has declined to unmeasurable levels, suggesting an important role for propagation of preexisting injury rather than de novo direct injury 13 . Targeting the propagation of direct hepatocyte injury may represent a generalizable strategy for limiting the severity of dose-dependent and potentially idiosyncratic DILI. However, current efforts have been limited by inadequate knowledge of the molecular details underlying DILI propagation.
Recent work by our group and others have demonstrated a link between hepatic gap junctions, molecular channels composed of connexin proteins (Cx) that enable direct intercellular communication between coupled cells 14 and the amplification of liver inflammation 15, 16 . Based on these findings, we hypothesized that liver-specific gap junction inhibitors might act as 'hepatoprotectants' that can be coformulated with hepatotoxic drugs to prevent progression of liver injury.
We first examined the dependency of chemical-induced hepatotoxicity on connexin 32 (Cx32), the predominant gap junction protein expressed in the liver. Cx32-deficient (Cx32 −/− ) and wild-type (WT) (Cx32 +/+ ) mice were treated with a single dose of thioacetamide (TAA), a classic hepatotoxin known to cause fulminant hepatic failure. After 24 h, Cx32 +/+ mice had significantly elevated serum ALT/AST levels, indicative of severe hepatocellular damage, whereas Cx32 −/− mice exhibited near-normal levels of ALT/AST and substantially less histological evidence of parenchymal damage in the liver (Fig. 1a-c) . The livers of Cx32 +/+ mice displayed a classic perivenular pattern of injury that extended into the hepatic lobule, whereas Cx32 −/− mice exhibited only a small, localized perivenular ring of injury and necrosis that did not extensively radiate throughout the hepatic lobule (Fig. 1c) . The overall inflammatory response of the liver and the associated recruitment of neutrophils were also attenuated in Cx32 −/− mice (Fig. 1d,e) . This decreased hepatotoxicity in Cx32 −/− mice strongly reduced TAAinduced mortality. Treatment of Cx32 +/+ mice with a lethal dose of TAA resulted in 100% mortality, compared to a 100% survival in Cx32 −/− mice (Fig. 1f) . We confirmed that the protective effects of l e t t e r s gap junction deficiency were not simply a result of defective drug metabolism by showing that serum concentrations of TAA and its toxic metabolite were the same in Cx32 +/+ and Cx32 −/− mice, as was phase I cytochrome P450 and phase II GST activity ( Supplementary  Figs. 1 and 2) . Together, these results demonstrate that Cx32 is an essential mediator of chemical-induced liver injury and suggest that Cx32 inhibition might be a viable strategy for preventing hepatotoxic effects of drugs.
Given the unique spatial distribution of both the injury and protection observed in the livers of Cx32 +/+ and Cx32 −/− mice, respectively, we hypothesized that gap junction communication might promote the propagation and amplification of an injury signal after TAA treatment. Because oxidative stress is a well-established consequence of hepatotoxin exposure 17, 18 and free radicals are known to propagate through gap junctions, we considered the possibility that gap junctions amplify liver injury by promoting the propagation of an oxidative stress signal throughout the parenchyma. We first demonstrated the dependence of DILI on oxidative stress by showing that two potent antioxidants, DMSO and NAC, reduce liver injury when co-administered with TAA or acetaminophen, respectively ( Supplementary Fig. 3 ), and then compared the burden of intracellular free radicals in the livers of Cx32 +/+ and Cx32 −/− mice ( Supplementary Fig. 4 ). We found that livers of TAA-treated Cx32 +/+ mice exhibited intense focal regions of reactive oxygen species (ROS) activity, whereas those of Cx32 −/− mice showed comparatively little activity (Supplementary Fig. 4a ). We next devised an in vitro co-culture system to test whether hepatotoxin-exposed cells require Cx32 to propagate an oxidative stress signal to surrounding unexposed neighbors ( Supplementary Fig. 4b,c) . Connexindeficient HeLa cells (HeLa WT) and Cx32-expressing HeLa cells (HeLa Cx32) were stimulated with the reactive metabolite of TAA (thioacetamide sulfoxide; TASO) in the presence or absence of free radical scavengers 18 , and plated onto the Cx32-expressing hepatocyte-derived H35 cells preloaded with a fluorescent ROS probe ( Supplementary Fig. 4c ). Using this co-culture system, we detected ROS in unexposed neighbors only when they came into contact with TASO-exposed cells expressing Cx32, and found that this effect is prevented by pretreating the TASO-exposed cells with free radical scavengers ( Supplementary Fig. 4d ). Together these results suggest that Cx32 gap junctions propagate hepatotoxininduced oxidative stress between hepatocytes.
To investigate the therapeutic potential of Cx32 inhibition for preventing hepatotoxicity, we used a cell-based co-culture assay to screen chemical libraries for small-molecule inhibitors of Cx32 that could be administered to WT mice to achieve the same hepatoprotection observed in the Cx32 deficient mice. We identified 2-aminoethoxydipenyl-borate (2APB), a compound previously shown to transiently inhibit Cx32 gap junctions in vitro 19 . We determined the specificity of 2APB for Cx32 gap junctions by performing a calcein-AM dyecoupling 'parachute' assay using Cx32-and Cx43-expressing HeLa cells (HeLa Cx32, HeLa Cx43). Treatment with 2APB blocked the spread of calcein through Cx32 gap junctions, but had a modest effect on Cx43 gap junctions (Fig. 2a,b) . We then adapted the classic 'scrape and load' gap junction intercellular communication assay, which entails localized mechanical disruption of a cohesive network of cells (scrape) and subsequent administration of a dye that can propagate only through gap junctions (load), to explanted liver slices from Cx32 +/+ and Cx32 −/− mice, and demonstrated that 2APB effectively blocks hepatic gap junction communication in vivo (Fig. 2c) .
We next examined the effect of 2APB pretreatment of TAA-and acetaminophen-induced liver injury. Acetaminophen is the active ingredient in several common over-the-counter and prescription pain medications. When WT mice were pretreated with a single dose of 2APB 60 min before challenge with TAA or acetaminophen, the hepatoprotective response was strikingly similar to that observed in Cx32 −/− mice. Compared to DMSO vehicle-treated mice, those that received 2APB exhibited significantly less serum ALT and much less histological evidence of hepatocellular injury and necrosis (Fig. 2d-g ). We confirmed that the hepatoprotective effect of 2APB was not a result of defective drug metabolism by showing that serum concentrations of TAA and TASO were similar in mice treated with DMSO vehicle or 2APB (Supplementary Fig. 1 ). These findings demonstrate l e t t e r s that 2APB is an effective hepatoprotectant, and support the hypothesis that targeting the Cx32 gap junction pathway with small-molecule inhibitors represents a viable strategy for limiting DILI.
As pretreatment strategies for reducing drug hepatotoxicity have limited practical utility in the clinic, we considered a coadministration strategy in which efficacious but potentially hepatotoxic drugs are coformulated with hepatoprotectants such as 2APB to improve their safety profiles. To develop this strategy, we used acetaminophen, the most common cause of death due to acute liver failure 20 . We administered known hepatotoxic drugs (acetaminophen or TAA) with the hepatoprotectant 2APB to WT mice, and compared their responses to mice receiving acetaminophen or TAA with the appropriate DMSO vehicle. Coadministration of 2APB with either acetaminophen or TAA strongly reduced serum ALT, total hepatic free radicals levels, histological evidence of hepatic necrosis and hemorrhage, liver inflammation, and neutrophil infiltration to near-normal levels (Fig. 3a-d and Supplementary Fig. 5 ). Coadministration of 2APB reduced acetaminophen -induced mortality from 80% to 30%, and TAAinduced mortality from 100% to 0% (Fig. 3e) . Furthermore, we confirmed that the hepatoprotective effect of 2APB was not a result of its vehicle, DMSO, by changing the vehicle to ethanol ( Supplementary  Fig. 6 ). Together, these results suggest a strategy in which potential hepatotoxic drugs are coformulated with hepatoprotectants, such as Cx32 inhibitors, to improve their overall safety profile and reduce the clinical incidence of DILI.
Although coformulation of hepatotoxic compounds with gap junction inhibitors is an attractive strategy for future drug development, it is not directly applicable to patients seeking treatment after ingestion of compounds such as acetaminophen at hepatotoxic doses. Therefore, we examined whether Cx32 inhibition could rescue hepatotoxicity after drug ingestion. Single injections of 2APB or a DMSO vehicle were given at various times after challenge with either acetaminophen or TAA. Mice treated with 2APB 1.5 h after either acetaminophen or TAA administration showed a nearly complete absence of hepatotoxicity (Fig. 3f,g) . Even when administered 6 h after hepatotoxin exposure, when hepatic necrosis is already evident and toxin metabolism is completed, 2APB rescue therapy reduced serum ALT levels and limited hepatocellular damage and necrosis (Fig. 3f,g ). These findings demonstrate that hepatic gap junction inhibition with potent small compounds such as 2APB, successfully rescues mice from DILI and may provide a clinically useful means to treat liver injury associated with dose-dependent hepatotoxic drugs such as acetaminophen. However, the specificity of 2APB needs further investigation, as hepatoprotection might be occurring by means of various mechanisms, including, but not limited to, gap junction inhibition.
Drug-induced hepatotoxicity is classically divided into dosedependent and idiosyncratic liver injury. The prototypical dosedependent hepatotoxin, acetaminophen, is the most common cause of DILI and is responsible for approximately half of the cases of acute liver failure 3, 20 . In contrast, idiosyncratic DILI involves over 900 clinically available drugs, but does so at a low incidence and in an unpredictable fashion 2 . Consequently, there are no prototypical idiopathic hepatotoxins and no experimental animal models of idiopathic DILI with which to study its pathogenesis or develop new therapies 21 . The strategy described here was developed in the context of dose-dependent hepatotoxins such as acetaminophen, because of their clinical importance as well as their experimental accessibility. Given that the strategy targets the propagation phase of DILI, it is possible that the findings have applicability in cases of idiosyncratic DILI. Such generalizability was previously demonstrated for N-acetylcysteine (NAC), which was originally developed as an antidote for dose-dependent acetaminophen hepatotoxicity, but has also shown npg l e t t e r s benefit in the treatment of patients with non-acetaminophen-induced acute liver failure 22 . Additionally, recent evidence suggests that dosedependent and idiosyncratic DILI may share some common modes of action and therefore potentially benefit from similar therapies 23 .
Applications for hepatoprotectants such as 2APB range from early drug development to clinical medicine. In the pharmaceutical industry, coformulation and coadministration has previously been used to reduce gastrointestinal 24 and renal toxicity 25 but it has yet to be applied to hepatotoxicity, the most common reason for abandoning efficacious compounds during preclinical and clinical trials. Coformulation of hepatoprotectants such as 2APB with potential hepatotoxins represents a promising strategy for rescuing compounds in the drug development pipeline by improving their safety profiles. In clinical medicine, the hepatoprotectant coadministration strategy might be used to allow continuation of medications such as statins, antibiotics, anti-epileptics or anti-tuberculosis drugs when they provoke elevations in liver enzymes or when they must be given to patients with preexisting liver disease. Finally, the most immediate clinical application of hepatoprotectants such as 2APB is in the acute management of acetaminophen overdose. Currently, the only available therapies are NAC, supportive care and liver transplantation. We demonstrated that 2APB can prevent and even rescue mice from death due to acetaminophen toxicity, adding to the therapeutic armamentarium for treatment of this frequently fatal condition. Whereas NAC provides hepatoprotection as a nonspecific anti-oxidant, 2APB protects the liver from injury by inhibiting hepatic gap junctions and blocking the propagation of oxidative stress in hepatocytes. It remains unclear to what extent 2APB will be helpful in idiosyncratic DILI as there are no animals models. However, early success treating nonacetaminophen DILI with NAC suggests the potential for generalization from dose-dependent to idiosyncratic DILI 22 . These applications represent promising areas for further research.
Gap junctions represent an elegant mechanism for enabling direct communication between neighboring cells. In some organs such as the heart, gap junctions have a clearly identified physiological role 26 and clinical trials of modulators are currently in progress such as a phase 2 trial of a gap junction inhibitor intended to prevent life-threatening arrhythmias after myocardial infarction 27 . In the liver, however, the role of gap junctions remains poorly understood. Here we show that progression of DILI is gap junction dependent and that Cx32 plays an essential role in amplifying injury, making it a promising therapeutic target for hepatoprotection.
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